NeuroSense Therapeutics (NASDAQ:NRSN) Rating Increased to Strong-Buy at D Boral Capital

D Boral Capital upgraded shares of NeuroSense Therapeutics (NASDAQ:NRSN) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Separately, D. Boral Capital started coverage on shares of NeuroSense Therapeutics in a research report on Monday. They set a “buy” rating and a $14.00 target price on the stock.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ:NRSN opened at $1.22 on Monday. The firm has a market cap of $16.64 million, a price-to-earnings ratio of -1.90 and a beta of 1.36. The firm has a fifty day moving average price of $1.04 and a 200 day moving average price of $1.10. NeuroSense Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.50.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings results on Monday, April 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06.

Institutional Trading of NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned approximately 0.47% of NeuroSense Therapeutics at the end of the most recent reporting period. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.